Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study

被引:116
|
作者
Hon, K. L. E. [1 ]
Leung, T. F.
Ng, P. C.
Lam, M. C. A.
Kam, W. Y. C.
Wong, K. Y.
Lee, K. C. K.
Sung, Y. T.
Cheng, K. F.
Fok, T. F.
Fung, K. P.
Leung, P. C.
机构
[1] Chinese Univ Hong Kong, Sch Pharm, Dept Paediat, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Hong Kong, Peoples R China
关键词
atopic dermatitis; CDLQI (Children's Dermatology Life Quality Index); children; SCORAD (SCORing of atopic dermatitis); traditional Chinese herbal medicine;
D O I
10.1111/j.1365-2133.2007.07941.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background There has been considerable interest in traditional Chinese herbal medicine (TCHM) as a treatment for atopic dermatitis (AD). A twice-daily concoction of an ancestral formula containing five herbs has been found to be beneficial in an open study. Objectives To assess the efficacy and tolerability of the concoction in children with AD. Methods Following a 2-week run-in period, children with long-standing moderate-to-severe AD were randomized to receive a 12-week treatment with twice-daily dosing of three capsules of either TCHM or placebo. The SCORing of Atopic Dermatitis (SCORAD) score, Children's Dermatology Life Quality Index (CDLQI), allergic rhinitis score, and requirement for topical corticosteroid and oral antihistamine were assessed before and at weeks 4, 8, 12 and 16 after treatment. Adverse events, tolerability, haematological and biochemical parameters were monitored during the study. Results Eighty-five children with AD were recruited. Over 12 weeks, the mean SCORAD score fell from 58.3 to 49.7 in the TCHM group (n = 42; P = 0.003) and from 56.9 to 46.9 in the placebo group (n = 43; P = 0.001). However, there was no significant difference in the scores at the corresponding time points between the two groups. The CDLQI in TCHM-treated patients was significantly improved compared with patients receiving placebo at the end of the 3-month treatment and 4 weeks after stopping therapy (P = 0.008 and 0.059, respectively). The total amount of topical corticosteroid used was also significantly reduced by one-third in the TCHM group (P = 0.024). No serious adverse effects were observed between the groups. Conclusions The TCHM concoction is efficacious in improving quality of life and reducing topical corticosteroid use in children with moderate-to-severe AD. The formulation was palatable and well tolerated.
引用
收藏
页码:357 / 363
页数:7
相关论文
共 50 条
  • [21] Chinese herbal medicine for chronic heart failure:a multicenter, randomized,double-blind, placebo-controlled trial
    Liangtao Luo
    Juan Wang
    Aiqing Han
    Peng Zhang
    Shuzhen Guo
    Chan Chen
    Xuegong Xu
    Qian Lin
    Huihui Zhao
    Wei Wang
    Journal of Traditional Chinese Medical Sciences, 2014, 1 (02) : 98 - 108
  • [22] Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study
    Zhang, Zhang-Jin
    Kang, Wan-Hu
    Tan, Qing-Rong
    Li, Qiang
    Gao, Cheng-Ge
    Zhang, Feng-Gang
    Wang, Huai-Hai
    Ma, Xian-Cang
    Chen, Ce
    Wang, Wei
    Guo, Li
    Zhang, Ya-Hong
    Yang, Xiao-Bo
    Yang, Guang-De
    JOURNAL OF PSYCHIATRIC RESEARCH, 2007, 41 (3-4) : 360 - 369
  • [23] Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study
    Wiebrecht, Axel
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2007, 50 (03): : 50 - 51
  • [24] The Efficacy of a Traditional Herbal Medicine Compound for Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial
    Samimi, Soodabeh
    Nimrouzi, Majid
    Zarshenas, Mohammad Mehdi
    Fallahzadeh, Ebrahim
    Vardanjani, Hossein Molavi
    Sadeghi, Erfan
    Salehi, Zahra
    JUNDISHAPUR JOURNAL OF NATURAL PHARMACEUTICAL PRODUCTS, 2024, 19 (04)
  • [25] DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF LOCAL CYCLOSPORINE IN ATOPIC-DERMATITIS
    DEPROST, Y
    BODEMER, C
    TEILLAC, D
    ARCHIVES OF DERMATOLOGY, 1989, 125 (04) : 570 - 570
  • [26] Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis
    Pittler, MH
    Armstrong, NC
    Cox, A
    Collier, PM
    Hart, A
    Ernst, E
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) : 307 - 313
  • [27] CETACAINE EFFICACY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    LACHTER, J
    JACOBS, R
    LAVY, A
    SUISSA, A
    WEISLER, A
    EIDELMAN, S
    GASTROENTEROLOGY, 1988, 94 (05) : A245 - A245
  • [28] Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial
    Fujimura, M.
    Ishimaru, H.
    Nakatsuji, Y.
    POLISH JOURNAL OF VETERINARY SCIENCES, 2014, 17 (02): : 371 - 373
  • [29] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF LOCAL CYCLOSPORINE IN ATOPIC-DERMATITIS
    DEPROST, Y
    BODEMER, C
    TEILLAC, D
    ACTA DERMATO-VENEREOLOGICA, 1989, : 136 - 138
  • [30] Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial
    Veien, NK
    Busch-Sorensen, M
    Stausbol-Gron, B
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) : 147 - 149